Last reviewed · How we verify
HUC2-565-A, HUC2-565-A and HUC2-565-B — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
HUC2-565-A, HUC2-565-A and HUC2-565-B (HUC2-565-A, HUC2-565-A and HUC2-565-B) — Huons Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HUC2-565-A, HUC2-565-A and HUC2-565-B TARGET | HUC2-565-A, HUC2-565-A and HUC2-565-B | Huons Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HUC2-565-A, HUC2-565-A and HUC2-565-B CI watch — RSS
- HUC2-565-A, HUC2-565-A and HUC2-565-B CI watch — Atom
- HUC2-565-A, HUC2-565-A and HUC2-565-B CI watch — JSON
- HUC2-565-A, HUC2-565-A and HUC2-565-B alone — RSS
Cite this brief
Drug Landscape (2026). HUC2-565-A, HUC2-565-A and HUC2-565-B — Competitive Intelligence Brief. https://druglandscape.com/ci/huc2-565-a-huc2-565-a-and-huc2-565-b. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab